Pfizer announced the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion, recommending marketing authorization for TRAZIMERA, a potential biosimilar to Herceptin, for the treatment of HER2 overexpressing breast cancer and HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.